E&Y: Biotech business model crumbles as crisis hits
Ernst & Young has come out with its annual review of the biotech industry and it reads more like a progress report on a trip through the Valley of Death. The accounting firm concludes that the biotech business model is 'unsustainable' in a crisis like this.
E&Y firm has totaled the numbers for biotech companies and has reached harsh bottom line: An unprecedented number of biotech companies will go broke this year, forcing many to sell out and others to close their doors. In addition, developers in Europe and the U.S. raised $16 billion last year, a 46 percent plunge.
Altogether 162 publicly traded biotech companies--a whopping 44 percent of the total--have less than a year's worth of operating capital in the bank at the end of last year. That's up from 25 percent a year earlier. And the cash crunch is coming at a time that traditional sources of investment funds are drying up fast.
"This time around we have a much deeper, more systemic financing crisis," Glen Giovannetti, global biotech leader at Ernst & Young, tells Reuters. "The recovery won't come fast enough for some companies." And the biotech expert says that even though a slate of big pharma companies are prowling the market for new acquisitions, weak developers with shaky programs are likely to find themselves out of the game.
The silver lining: Revenue at the public biotechs has jumped 12 percent and the industry's net loss was shaved 53 percent.
The barbarian investors are at biotech's gates
The credit crisis hits home
Credit crisis pushes biotechs to the brink
More biotech bankruptcies on the horizon
VC dollars down 47 percent in Q1 2009